Claritev (NYSE:CTEV) Price Target Raised to $43.00

Claritev (NYSE:CTEV) had its target price raised by Canaccord Genuity Group from $37.00 to $43.00 in a report released on Monday morning, MarketBeat reports. They currently have a buy rating on the stock.

A number of other analysts have also weighed in on CTEV. Zacks Research lowered Claritev from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. Citigroup reiterated a “buy” rating and issued a $45.00 target price (up from $40.00) on shares of Claritev in a report on Monday. Wall Street Zen upgraded Claritev from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a research report on Wednesday, June 24th. Finally, Piper Sandler set a $61.00 price objective on Claritev in a research note on Wednesday, June 3rd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Claritev currently has a consensus rating of “Hold” and an average target price of $42.83.

Claritev Stock Up 0.3%

Claritev stock opened at $35.06 on Monday. The firm has a market cap of $597.77 million, a PE ratio of -2.06 and a beta of 0.74. Claritev has a 52-week low of $11.50 and a 52-week high of $74.07. The company’s 50 day moving average is $29.32 and its two-hundred day moving average is $23.86.

Insider Activity

In other news, SVP William B. Mintz sold 8,431 shares of Claritev stock in a transaction on Monday, August 10th. The shares were sold at an average price of $34.24, for a total transaction of $288,677.44. Following the completion of the sale, the senior vice president directly owned 71,195 shares of the company’s stock, valued at approximately $2,437,716.80. The trade was a 10.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.40% of the company’s stock.

Institutional Trading of Claritev

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new position in shares of Claritev in the 3rd quarter valued at about $1,245,000. Vanguard Group Inc. purchased a new stake in Claritev during the third quarter worth approximately $27,483,000. Ameritas Investment Partners Inc. purchased a new stake in Claritev during the third quarter worth approximately $42,000. Russell Investments Group Ltd. acquired a new position in Claritev in the third quarter valued at approximately $369,000. Finally, Legal & General Group Plc acquired a new position in Claritev in the third quarter valued at approximately $45,000. 87.15% of the stock is owned by hedge funds and other institutional investors.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.